Sci-Tech Innovation 200 ETF Penghua(588240) up over 3.4%, biomedical sector remains active

Bio-medical and pharmaceutical innovation remains active. On the news front, this year more than 100 Chinese pharmaceutical companies have appeared at AACR, bringing nearly 400 research results, covering many current popular targets. Frontier technologies such as radiopharmaceuticals, DAC, cell therapy, mRNA, and others are represented.

CITIC Securities believes that, as a strategic emerging industry, biopharmaceuticals are poised to benefit from long-term development opportunities under the support of the “14th Five-Year Plan.” Policies explicitly support the clinical use of innovative drugs and frontier technologies such as brain-computer interfaces. Coupled with rising costs accelerating industry consolidation, leading companies with innovation and internationalization will have greater advantages.

As of 14:00 on April 1, 2026, the SSE STAR Market 200 Index (000699) rose strongly by 3.67%. Among constituent stocks, DingTong Technology increased by 18.19%, AiDi Pharma by 16.77%, HuiYu Pharma by 16.11%, and stocks such as Warner Pharma Factory and YuanDong Bio also gained. The Penghua SSE STAR Market 200 ETF (588240) increased by 3.44%, with the latest price at 1.53 yuan.

The Penghua SSE STAR Market 200 ETF closely tracks the SSE STAR Market 200 Index. The SSE STAR Market 200 Index selects 200 securities from the Shanghai Stock Exchange’s STAR Market with relatively smaller market capitalization and better liquidity as its sample. The SSE STAR Market 200 Index, together with the SSE STAR Market 50 constituent index and the SSE STAR Market 100 index, forms the SSE STAR Market capitalization index series, reflecting the overall performance of listed companies across different market-cap segments on the STAR Market.

The Penghua SSE STAR Market 200 ETF (588240) features three key characteristics: the “hard technology” logic, opportunities in “small and micro caps,” and the “20% limit-up/limit-down board” leverage—making it the “vanguard” in historical rebound rallies. The STAR Market 200 Index gathers potential dark-horse stocks. Industry distribution is balanced and diverse, with the medical sector accounting for nearly 15%. As of March 27, 2026, since the “9.24” rally, the index has increased by 162.69%, and since 2025, it has risen by 73.99%. These gains far surpass major small and micro-cap indices such as CSI 1000, CSI 2000, GuoZheng 2000, and ChiNext 200, and it also outperforms the Beizheng 50.

Data shows that as of March 31, 2026, the top ten holdings of the SSE STAR Market 200 Index (000699) are Chang Guang Huaxin, TengJing Technology, Juguang Technology, DeKeLi, JingZhiDa, YouKeDe, JiePuTe, JiaYuan Technology, JuHe Materials, and WeiCe Technology. The combined weight of these top ten stocks accounts for 16.73%.

Penghua SSE STAR Market 200 ETF (588240), OTC connection (A: 023926; C: 023927).

A wealth of information and precise analysis—only on the Sina Finance App